(Q36568724)

15 August 2017

1 reference

title

Effective regimens for the treatment of Helicobacter pylori infection (English)

1 reference

Helicobacter pylori infectious disease

15 August 2017

1 reference

1 reference

Andrea Morgner

1

1 reference

15 August 2017

Joachim Labenz

series ordinal

2

1 reference

15 August 2017

Stephan Miehlke

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

15

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

995-1016

1 reference

Helicobacter pylori in duodenal and gastric ulcer disease

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Causal role of Helicobacter pylori infection and eradication therapy in gastric carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Long-term follow-up of gastric MALT lymphoma after H. pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Review article: Helicobacter pylori and gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Prevention and treatment of NSAID-induced gastroduodenal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Guidelines in the management of Helicobacter pylori infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Review article: the treatment of refractory Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Selection of lower cutoff point of [13C]urea breath test is helpful to monitor H. pylori eradication after proton pump inhibitor-based triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Esomeprazole‐based one‐week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Six regimens for the eradication of Helicobacter pylori (Hp) in duodenal ulcer patients: three consecutive trials (1995-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Strategy for treatment of Helicobacter pylori infection in adults. II. Practical policy in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

H pylori antibiotic resistance: prevalence, importance, and advances in testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

The status of antimicrobial resistance of Helicobacter pylori in eastern Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

In vitro selection of resistant Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Relevance of underlying disease and bacterial vacA and cagA status on the efficacy of Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Efficacy of Helicobacter pylori eradication therapies: a single centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Eradication of Helicobacter pylori in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Challenges to therapy in the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Helicobacter pylori "rescue" therapy after failure of two eradication treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Mechanisms of enteral nutrient-enhanced intestinal adaptation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Third-line rescue therapy with levofloxacin after two H. pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Rescue therapy with levofloxacin after multiple H. pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Adverse reactions to fluoroquinolones. an overview on mechanistic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Non-antibiotic therapies for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

High eradication rates of Helicobacter pylori with a new sequential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Clarithromycin-resistant genotypes and eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Use of lactoferrin for Helicobacter pylori eradication. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

MALT lymphoma: from morphology to molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Pathogenesis of Helicobacter pylori Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.995

Eradication of Helicobacter pylori for non-ulcer dyspepsia

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002096.PUB4

10.1517/13543784.15.9.995

12 January 2024

Identifiers

DOI

1 reference

15 August 2017

1 reference